Voyager Therapeutics on deck for IPO

• Voyager Therapeutics (NASDAQ:VYGR) is set for its IPO of 4,687,500 shares of common stock at $15 - 17.
• The clinical stage gene therapy firm develops treatments for severe diseases of the central nervous system (CNS), specifically those that are good candidates for an adeno-associated virus (AAV) gene therapy approach. Its lead product candidate is Phase 1-stage VY-AADC01 for advanced Parkinson's disease. Other pipeline candidates are VY-SOD101 for monogenic amyotrophic lateral sclerosis, VY-FXN01 for Friedreich's Ataxia, VY-HTT01 for Huntington's disease and VY-SMN101 for spinal muscular atrophy.
• 2015 Financials (6 mo.)($M): Collaboration Revenue: 7.5; Operating Expenses: 16.3 (+161.5%); Net Loss: (18.5) (-142.3%); CF Ops: 57.6 ($65M upfront payment from collaboration partner Genzyme).